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CHAPTER 1: INTRODUCTION
1.1 Introduction to Diabetes and Insulin Signaling Pathway

1.1.1 Introduction to Diabetes
Diabetes is a metabolic disorder characterized by hyperglycemia, high blood glucose
levels. In 2014, 29.1 million people in the United States had diabetes, out of which 21 million
were diagnosed and 8.1 million were undiagnosed [1]. Prediabetes is a condition in which the
blood sugar is high but not high enough to be considered diabetic and an estimated 86 million
people in the U.S has prediabetes [1]. In 2013, diabetes was ranked as the seventh leading cause
of death in the United States [1]. Other than elevated blood glucose levels, there are many other
complications associated with diabetes that affect a number of organs/tissues in the body. About
half of all people with diabetes have some form of diabetic neuropathy, nerve damage caused by
diabetes [2]. The chances of experiencing a stroke or developing heart disease are higher than
average for people with diabetes [3]. High levels of blood sugar, over time, can also lead to
diabetic nephropathy, a kidney disease [4]. Diabetic retinopathy occurs when there is a retina
disorder caused by diabetes [5].
There are two major classifications of diabetes, type 1 and type 2. Type 1 diabetes
accounts for about 5% of all diagnosed cases and Type 2 diabetes accounts for about 90% to
95% of all cases [1]. Type 1 diabetes, commonly known as juvenile diabetes, is when the body
produces little or no insulin due to the loss of pancreatic beta cells. This type of diabetes is
usually diagnosed in young adults and children. Type 2 diabetes is caused by relative insulin
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deficiency and insulin resistance, which is a condition when the body does not use insulin
properly. This type of diabetes is usually diagnosed in older adults.
Insulin is a hormone produced by the islet cells in the pancreas that regulates a wide
variety of biological processes like metabolism, growth and cell survival [6]. The majority of
insulin-stimulated glucose uptake occurs in the skeletal muscle [7]. Insulin resistance in the
skeletal muscle is one of the major defects in type 2 diabetes [8].

1.1.2 Insulin Signaling Pathway
Insulin increases glucose uptake in the muscle and fat and thus decreases blood sugar
levels [9]. It also increases the storage of energy reserves in fat, liver, and muscle through the
stimulation of lipogenesis, glycogen synthesis and protein synthesis [10]. These cellular responses
are a result of the activation of a number of different pathways that occur in the liver, muscle and
fat cells. Insulin binds to the insulin receptor (IR), a tyrosine kinase receptor, inducing a
structural change enabling autophosphorylation of the receptor to take place. Once
phosphorylated, the receptor phosphorylates various tyrosine residues on docking proteins [e.g.,
insulin receptor substrate 1 (IRS1), Shc and adaptor protein with PH and SH2 domain (APS)]
[11]

. Tyrosine phosphorylation of these substrates initiates the signaling of the phosphoinositide-3

kinase/Akt (PI 3K) and Ras/MAPK pathways [12]. In the PI 3K pathway, activated Akt/PKB
increases insulin-stimulated translocation of a glucose transporter (GLUT4) in the muscle and
adipose tissues [13]. Cell growth-related gene expression is regulated by the MAPK pathway
through a signaling cascade that is also activated by insulin [14].
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1.2 Protein Phosphatase 2A (PP2A) Regulation and Effects on
Insulin
Reversible phosphorylation of proteins is a major mechanism that regulates a large
number of intracellular events (like metabolism, transport and secretion, transcription and
translation of genes) in eukaryotic cells [15]. Phosphatases carry out dephosphorylation by
removing a phosphate group from phosphorylated serine, threonine and tyrosine residues,
leading to activation or deactivation of substrate proteins.
PP2A is one of the most abundant serine/threonine protein phosphatases, and is
responsible for regulating the activities of a large number of signal transduction proteins [16].
PP2A makes up as much as 1% of total cellular proteins and together with protein phosphatase 1
(PP1), accounts for >90% of all Ser/Thr phosphatase activities in most tissues and cells [17].
PP2A can exist in two different forms: a trimeric form [18] and a dimeric form [19]. The core
enzyme, dimeric form, consists of a 36kDa catalytic subunit C (PP2AC) and a 65 kDa scaffold
subunit A (PP2AA), while the trimeric form consists of the core enzyme and a 55kDa regulatory
subunit B (PP2AB) [20] (Fig 2). There are 4 types of regulatory B subunits: B (B55/PR55), B’
(B56/PR61), B’’ (PR48/PR72/PR130) and B’’’ (PR93/PR110), while the A and C subunits exist
in the α and β isoforms [17-20].

1.2.1 Regulation of PP2A
PP2A is regulated by subunit diversity, post-translational modifications, substrate protein
interactions and auto-regulation [21]. Due to a large number of potential associations of the A and
B regulatory subunits, a total of 75 dimeric and trimeric PP2A holoenzymes can be generated
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[22]

. The combination of the A, B and C subunit isoforms affects the activity and specificity of the

PP2A complex against a particular substrate.
Experiments done in vivo and in vitro have shown that phosphorylation of tyrosine307
inhibited the activity of PP2Ac by preventing its interaction with the regulatory subunit [21-23]. In
addition, methylation of Leu309 by leucine carboxylmethyltransferase 1 (LCMT1) has been
shown to enhance the binding affinity of the A and C subunits to distinct regulatory subunits [21,
22]

.
Various cellular proteins such as I1PP2A and I2PP2A regulate the activity of PP2A by

directly interacting with the free C subunit or with the AC core dimer [21-24]. Aside from cellular
proteins, some small compounds found naturally such as okadaic acid can inhibit the enzymatic
activity of PP2A [25].

1.2.2 PP2A in Insulin Signaling
The effect of insulin on PP2A abundance in the muscle of type 2 diabetic subjects was
shown by Højlund et al. They showed that upon insulin stimulation in vivo, PP2A levels in
control subjects were reduced (when compared to basal levels), but not in type 2 diabetic
subjects [16].
Saturated fatty acids like palmitate have been shown to negatively regulate insulin
signaling by activating PP2A [26-28]. Wu et al. observed a decrease in Thr172 phosphorylation of
AMPK, a substrate of PP2A, when bovine aortic endothelial cells (BAECs) were incubated with
palmitate [26]. In rat hepatocytes [27] and human skeletal muscle cells [28], treated with fatty acids,
PP2A was seen to have been upregulated and Akt phosphorylation and activation was decreased.
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PP2A activation was observed in INS-1 832/13, an insulin-secreting pancreatic β-cell line
[29]

and C2C12 skeletal myotubes [30] treated with ceramide. Cazzolli and associates observed a

reduction in glycogen synthesis through the inhibition of phosphorylation on Akt/PKB upon
insulin stimulation mediated through activated PP2A [30].
In the context of insulin signaling, PP2A interacts with various proteins involved in the
signaling cascade (e.g. AKT, GSK3, etc.). In recent studies, 514 proteins were identified as
PP2Ac interaction partners in pancreatic β-cells [31]. Of those 514 proteins, 89 proteins showed a
significant difference in response to glucotoxic treatment [31]. Some of those interaction partners
have been known to be involved in insulin secretion (Rab5c, RhoA), gluconeogenesis (WDR5)
and glucose flux control (GFPT1) [31].

1.3 Insulin Sensitivity and Protein-Protein Interactions

1.3.1 Measuring Insulin Sensitivity
Insulin sensitivity can be measured directly using hyperinsulinemic euglycemic clamp
and the insulin suppression test, and can be measured indirectly using minimal model analysis of
frequently sampled intravenous glucose tolerance test (FSIVGTT) and oral glucose tolerance test
(OGTT) [32].
Where the maintenance of steady-state conditions is crucial, the hyperinsulinemic
euglycemic clamp is considered the “gold standard” for measuring insulin sensitivity because it
directly measures the effects of insulin in vivo [33].
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1.3.2 Protein-protein interactions (PPIs)
Protein-protein complexes are an important component of various biological functions
such as cell cycle regulation, gene transcription, signal transduction [34], etc. Correct formation of
these complexes is necessary for normal body function. Abnormality in the formation of these
complexes can lead to irregular cell signals and ultimately cause diseases. Currently, scientists
are targeting protein complexes to treat diseases like Huntington’s disease [35]. Studying PPIs can
help us understand the function of a particular target protein and analyze the signaling pathways.
PPIs can be classified as homo-oligomeric and hetero-oligomeric based on the type of
protein units involved; non-obligate and obligate based on the stability of the structure, and
transient and permanent based on the lifetime of the complex [36].
These interactions can be detected using biochemical methods (like coimmunoprecipitation and chemical cross-linking) and biophysical methods (like NMR
Spectroscopy and X-ray crystallography). The most commonly used high-throughput methods
are yeast two-hybrid screening and affinity purification coupled to mass spectrometry [37-39].

1.4 Mass Spectrometry
Mass spectrometry is a powerful approach for the identification, characterization and
quantification of proteins [40]. This is a very sensitive technique that can be used to identify
compounds as low as 1 part per trillion in chemically complex mixtures and as small as 10-12 g
for a compound of mass 1000Da [40]. The main components of a mass spectrometer include an
ion source, a mass analyzer and a detector.
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1. Ion Source: This device generates charged particles and the two commonly used ion
sources are Matrix-Assisted Laser Desorption Ionization (MALDI) and Electrospray
Ionization (ESI) [40].
2. Mass Analyzer: This is used to separate ions based on their mass-to-charge ratio. A few
commonly used mass analyzers include quadrupole, ion trap, orbitrap analyzers, etc. [40].
3. Detector: This device is used to record the charge induced when the ion hits a surface (for
example the electron multiplier) or record the current produced when the ion passes by
(for example the image current detector) [40].
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CHAPTER 2: RESEARCH DESIGN AND METHODS
Clinical and proteomics data acquisition and data analysis used for this project were
illustrated in Fig. 3. First, we recruited subjects and performed comprehensive screening tests
(Visit 1) to ensure patient eligibility. This was then followed by in-patient clinical tests (Visit 2)
which included the hyperinsulinemic-euglycemic clamp and muscle biopsies. The skeletal
muscle cells collected were analyzed in the following order: homogenization of the biopsy
sample; immunoprecipitation of PP2Ac; the eluate were subjected to in-solution trypsin
digestion, peptide extraction and UPLC-nanoESI-MS/MS analysis to identify coimmunoprecipitating proteins. Immunoprecipitation of NIgG (non-specific control) was carried
out to minimize the possibility of obtaining false positive results.

2.1 Materials
2.1.1 Reagents
Reagents were acquired from these suppliers: sequencing-grade modified trypsin
(Promega, Madison, WI); protein A sepharose, protein G-agarose and iodoacetamide (Sigma, St
Louis, MO); C18 ziptip (Millipore, Billerica, MA); Normal mouse IgG antibody, anti-PP2A Csubunit antibody and PP2A Immunoprecipitation phosphatase assay kit (Millipore, Billerica,
MA).

2.1.2 Subjects
A total of 8 volunteers –glucose tolerant lean controls (LC)—were recruited and took part
in the study at the Clinical Research Center at Wayne State University. The study was explained
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in detail, including potential risks, to all participants and written consent was obtained before
participation. None of the participants engaged in heavy exercise, nor did they have any
significant medical problems. All forms of exercise were stopped at least 2 days before the study.
The protocol was approved by the Institutional Review Board of Wayne State University.

2.1.3 Hyperinsulinemic-Euglycemic Clamp with muscle biopsies
To determine insulin sensitivity and expose the skeletal muscle to insulin in vivo, a
hyperinsulinemic-euglycemic clamp was used, as previously described [41]. Having the
participant fast for a minimum of ten hours overnight, the study began around 08:30 hours (time
-60 mins). One catheter was placed in each arm, one to maintain the infusion of insulin and
glucose throughout the study; the second was used to collect blood to observe the participants
blood glucose levels. At 09:00 hours (time -30mins), a biopsy of the vastus lateralis muscle was
performed. As soon as possible, the biopsy samples were cleaned of blood, connective tissue and
fat, and then transferred to ice cold PBS for primary cell culture. At 09:30 hours (time 0 mins), a
second muscle biopsy was taken and then continuous human insulin (Humulin R; Eli Lilly,
Indianapolis, IN) infusion began and continued for 120 mins. The plasma glucose was measured
every five 5 minutes throughout the clamp. Throughout the insulin infusion, euglycemia was
maintained at ∼90 mg/dl. At 11:30 hours (time 120), the third muscle biopsy was taken and the
insulin infusion was shut off.
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2.2 Sample Preparation and Analysis
2.2.1 Sample Preparation
Cultured cells from the skeletal muscle biopsies were generated from the 8 human muscle
biopsies, and myoblasts were differentiated into myotubes in normal or hyperinsulinemic
hyperglycemic condition; Each condition was stimulated with or without insulin for 15 minutes
before harvesting the cells (cells were treated with the HGHI media to induce insulin resistance
[41-43]

). Therefore, there were four sets of samples: low glucose no insulin without acute 15-min

insulin treatment (LGNI BAS), low glucose no insulin with acute 15-min insulin treatment
(LGNI INS), high glucose high insulin without acute 15-min insulin stimulation (HGHI BAS)
and high glucose high insulin with acute 15-min insulin stimulation (HGHI INS). Cells were
then collected, homogenized and processed as described [44-46]. The lysate proteins were
precleared with NIgG and then followed by a PP2Ac immunoprecipitation. The
immunoprecipitates were washed three times in 700µL TBS. Once all the TBS solution was
removed, the immunoprecipitates were boiled in 30µL SDS buffer and transferred to a 0.5mL
centrifugal filter unit in a collection tube. The samples were then washed three times with 200µL
8M Urea, followed by three washes with 200µL 40mM ammonium bicarbonate (ABC). In
solution trypsin digestion was then carried out by adding 50µL trypsin in ABC and incubated
overnight at 37°C on a shaker. More ABC was added to the sample, and supernatant containing
tryptic peptides were transferred to a collection tube, and placed in a vacuum centrifuge until the
peptides were completely dried. The peptides were reconstituted in 0.1% TFA in water and
purified using a C18 ziptip. UPLC-nanoESI analysis using an Orbitrap Fusion Lumos, as
previously described [44], was performed.
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2.2.2 Sample Data Analysis
Using the MaxQuant software [47-50], peptide/protein identification and quantification
were performed. Using label-free quantification (LFQ), peak areas for each protein was obtained
and only proteins with a minimum of 2 unique peptides and a false discovery rate (FDR) at 0.01
were considered. In total, 1933 proteins were identified in the 32 samples in addition to the two
isoforms of PP2Ac, PP2Acα and PP2Acβ. To be considered as a PP2A interaction partner, the
following criteria needed to be satisfied: i) an enrichment ratio >10 and 1063 out of the 1933
proteins satisfy this criterion; ii) identified with LFQ peak area in more than half of the PP2Ac IP
(i.e. >16 out of 32 samples used), and 202 out of the 1063 proteins satisfy this criterion, and were
classified as PP2Ac interaction partner. The enrichment ratio was calculated as follows:
First, peak area for a protein identified in a sample was normalized against the sum of the
peak areas for all the proteins identified in that sample to obtain a normalized ratio for the
individual protein, Norm: i.
: =

∑

Then, the average of normalized ratio for each protein in the PP2Ac IP, Average_Norm:
i_PP2Ac, as well as the average of normalized ratio for the same protein in the NIgG IP,
Average_Norm: i_NIgG, were obtained. Finally, Average_Norm: i_PP2Ac was divided by
Average_Norm: i_NIgG, which gives the enrichment ratio for each protein.
ℎ

: =

Average_Norm: i_PP2Ac
Average_Norm: i_NIgG

Since NIgG was employed as a negative control, proteins exclusively detected in the
PP2Ac immunoprecipitates were classified as PP2Ac interaction partners. However, this would
lead to false negatives because the high sensitivity of our approach would identify a trace amount
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of a protein non-specifically absorbed on the NIgG beads. However, if this protein is a true
PP2Ac interaction partner, higher peak area will be assigned to this protein in the PP2Ac sample
than in the NIgG sample.
To determine the relative quantities of PP2Ac interaction partners in the samples, the
peak area for each protein identified in a specific sample was normalized against the peak area
for PP2Ac identified in the same sample, Norm: j.
:' =

(

_

2

The normalization strategy is widely used in proteomics studies involving protein-protein
interactions [49]. The normalized peak area for each PP2Ac interaction partner, Norm: j, was
compared among the 4 sets of samples to assess the effects of acute insulin stimulation and /or
chronicle hyperinsulinemia and hyperglycemia on protein-protein interactions involving PP2Ac.

2.2.3 Statistical Analysis
Although a large number of proteins were assigned in at least one of the 32 samples that
were studied, a number of filters were applied to narrow down the total number of proteins that
were used to compare the effects of acute insulin stimulation and /or chronicle hyperinsulinemia
and hyperglycemia among the 4 sets of samples (Figure 4). Statistical calculations were
performed using the paired t-test and changes were considered significant at p<0.05.
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CHAPTER 3: RESULTS
Clinical characteristics of the eight glucose tolerant lean control participants are listed in
Table 1. The participants’ average BMI is below 25kg/m2, HbA1c below 5.7 %, fasting plasma
glucose below 100 mg/dl, 2h OGTT below 100 mg/dl, indicating there are indeed lean healthy
non-diabetic controls. In addition, the mean M-value is at 11.0 mg/kg·min, suggesting they are
insulin sensitive.

3.1 PP2Ac interaction partners in primary skeletal muscle cells from glucose
tolerant lean human participants
PP2Acα and PP2Acβ were detected in PP2Ac immunoprecipitates from all 32 samples,
but were not detected in all the NIgG immunoprecipitates. In total, 202 proteins met the criteria
for classification as PP2Ac interaction partners (Figure 4 and Table 2).
Among the 202 interaction partners, 18 proteins were previously reported as PP2Ac
interaction partners in islet beta cells. The known interaction partners include ACP1, CCDC6,
DLST, GMPPB, IGBP1, NAMPT, PCBP2, PCBP3, PDHX, PPP2R1A, PPP2R2A, PPP4C,
PPP4R2, PSMA6, SSBP1, TUBB6, VPS25 and VTA1.
DAVID pathway analysis on the 202 interaction partners and PP2Ac showed a number of
pathways significantly enriched when compared to the whole genome background, such as
pyruvate metabolism, cytoskeleton organization and FGF signaling pathway (Figure 5 and Table
3).
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3.2 Nineteen interaction partners of PP2Ac with a significant difference
among 4 treatment groups.
A total of 19 interaction partners showed a significant change in PP2Ac interaction
among the 4 sets of samples (Table 4 and Figure 6). Under basal conditions (i.e., without acute
15-minute insulin stimulation), 6 proteins showed a significant change in PP2Ac interaction
between the low glucose no insulin and chronicle hyperinsulinemia and hyperglycemia
conditions (LGNI BAS vs HGHI BAS, p<0.05, Table 4 and Figure 6). Among these 19 partners,
2 proteins showed significant difference in PP2Ac interaction in LGNI condition in response to
insulin stimulation (LGNI BAS vs LGNI INS, p<0.05, Table 4 and Figure 6). In HGHI
conditions, 4 proteins showed significant difference in PP2Ac interaction in response to insulin
stimulation (HGHI Bas vs HGHI INS, p<0.05, Table 4 and Figure 6). Upon acute insulin
stimulation, 11 proteins showed significant difference in PP2Ac interaction in HGHI condition
when compared to the LGNI condition (LGNI INS vs HGHI INS, p<0.05, Table 4 and Figure 6).
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CHAPTER 4: DISCUSSION
4.1 PP2Ac interaction partners in primary skeletal muscle cells from glucose
tolerant lean human participants
We have identified 202 PP2Ac interaction partners in the primary skeletal muscle cells of
8 glucose tolerant lean participants, using a proteomics approach developed in our laboratory [44].
Among them, 18 proteins are known PP2Ac interaction partners in islet beta cells recently
reported by our group (Table 2).
From these 18 PP2Ac interaction partners, PPP2R1A and PPP2R2A are A subunit alpha
isoform and B” subunit alpha isoform of the PP2A complex, respectively. DLST,
dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex), is a part of
the TCA cycle and is responsible for catalyzing the overall conversion of 2-oxoglutarate to
succinyl-CoA and CO2 [50]. PDHX, pyruvate dehydrogenase protein X component, is a part of
the PDH complex which provides the primary link between glycolysis and the TCA cycle by
catalyzing the irreversible conversion of pyruvate into acetyl-CoA [51]. GMPPB, GDP-mannose
pyrophosphorylase B, is an enzyme that catalyzes the reaction which converts mannose-1phophatase and GTP to GDP-mannose [52]. GDP-mannose is necessary for some glycosylation
pathways to occur. Glycosylation is a post translational modification of proteins that is important
for proper protein folding [53]. IGBP1, immunoglobulin (CD79A) binding protein 1 and also
known as alpha4, is involved in the regulation of the catalytic activity of PP2A by protecting its
partially folded catalytic subunits from degradative polyubiquitination [54, 55]. VPS25, vacuolar
protein-sorting-associated protein 25, is a protein that is part of the endosomal sorting complex
required for transporting II (ESCRT-II), which functions in the sorting of ubiquitinated
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membrane proteins during endocytosis [56]. VTA1, vacuolar protein sorting-associated protein
VTA1 homolog, is a protein in the ESCRT-IV complex that works in trafficking multivesicular
bodies [57, 58]. PSMA6, proteasome subunit alpha type-6, is a component of the 20S core
proteasome complex, which is involved in the proteolytic degradation of most intracellular
proteins [59]. NAMPT, nicotinamide phosphoribosyltransferase, belongs to the nicotinic acid
phosphoribosyl transferase (NAPRTase) family and is involved in many biological processes,
including metabolism, stress response and aging [60]. This protein catalyzes the condensation of
nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide (an
intermediate in the biosynthesis of NAD) [61]. SSBP1, single-stranded DNA-binding protein, is a
protein that is involved in mitochondrial biogenesis and a decrease in mitochondrial function can
lead to the aging, neurodegeneration and type 2 diabetes [62-64]. TUBB6, tubulin beta-6 chain, is a
constituent of microtubules, which helps to control insulin secretion and a disturbance in this
control can lead to beta cell dysfunction and type 2 diabetes [65]. PPP4C, serine/threonine-protein
phosphatase 4 catalytic subunit, is shown to play a role in microtubule organization at
centrosomes and PPP4R2, a regulatory subunit of PPP4C, helps regulate the activity of PPP4C
[66]

. PCBP2 and PCBP3, poly(rC)-binding protein 2 and poly(rC)-binding protein 3 respectively,

are major poly(rC)-binding proteins that negatively regulates cellular antiviral responses
mediated by the mitochondrial antiviral signaling pathway (MAVS) [67]. In connection to
diabetes, studies have shown an association between viral infections, like hepatitis C, with
diabetes [68].
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4.2 Nineteen interaction partners of PP2Ac with a significant difference
among 4 treatment groups.
Under basal conditions, 6 proteins showed a significant fold change in PP2Ac interaction
among the low glucose no insulin and high glucose high insulin conditions (LGNI BAS vs HGHI
BAS, p<0.05, Table 4 and Figure 6). Of these 6 proteins, 5 of them (ASTML, ESD, GLRX3,
HINT1 and QKI) showed increased association while only GPX1 showed decreased association.
QKI, protein quaking, is an RNA-binding protein that plays a central role in myelination, the
formation of myelin sheath around a nerve fiber [69]. Abnormalities in myelin formation can lead
to diabetic peripheral neuropathy [70]. GLRX3, glutaredoxin-3, is a part of the glutaredoxin
family and binds to and modulates the function of PKC-theta [71]. PKC theta has been shown to
induce insulin-mediated tightening of the muscles by inhibiting Akt [72]. GPX1, glutathione
peroxidase 1, protects cells against oxidative damage and has been shown to be upregulated by
IGF-1 in vascular endothelial cells [73]. ROS level elevation in diabetes may be due to decrease in
destruction or increase in the production by glutathione peroxidase antioxidant [74]. HINT1
(histidine triad nucleotide-binding protein 1), a tumor suppressor gene, inhibits the Wnt/βcatenin pathway [75] and has been shown to interact with IRS1, insulin receptor substrate 1, along
with PP2Ac in human skeletal muscle [44]. ESD, S-formylglutathione hydrolase, is an enzyme
that is involved in the detoxification of formaldehyde [76].
Among these 19 partners, 2 proteins showed significant difference in PP2Ac interaction
in the low glucose no insulin condition in response to insulin stimulation (LGNI BAS vs LGNI
INS, p<0.05, Table 4). Both CCDC6 and GLRX3 showed increased association with PP2Ac.
CCDC6 (coiled-coil domain containing 6), a tumor suppressor gene, is involved in apoptosis and
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DNA damage response [77]. GLRX3, as mentioned previously, is a part of the glutaredoxin
family and binds to and modulates the function of PKC-theta [71].
In hyperinsulinemia and hyperglycemia conditions, 4 proteins showed significant
difference in PP2Ac interaction in response to insulin stimulation (HGHI BAS vs HGHI INS,
p<0.05, Table 4). ACP1 and HINT1 both showed decreased association with PP2Ac, while
CYCS and HSPB6 showed increased association with PP2Ac. HSPB6, heat shock protein beta-6,
plays a role in regulating muscle function such as smooth muscle vasorelaxation and cardiac
myocyte contractility [78]. CYCS (cytochrome c), a small heme protein, is known to be involved
in electron transport chain in the mitochondria and involved in the initiation of apoptosis [79].
ACP1, low molecular weight phosphotyrosine protein phosphatase, is an acid phosphatase and
protein tyrosine phosphatase that plays an important role in the control of insulin receptor
activity [80].
Upon insulin stimulation, 11 proteins showed significant difference in PP2Ac interaction
in the hyperinsulinemia and hyperglycemia condition when compared to the LGNI condition
(LGNI INS vs HGHI INS, p<0.05, Table 4). All 11 proteins (TAK1L, DCAMKL1, ESD, GSS,
HINT1, IGBP1, SEP11, TPPP3, UCK2, GRIPAP1 and S100A13) showed decreased association
with PP2Ac. IGBP1, as previously mentioned, binds to PP2Ac to stabilize it [54, 55]. DCAMKL1,
doublecortin Like Kinase 1, is a kinase involved in the Ca2+ signaling pathway controlling
neuronal migration [81]. GRIPAP1, GRIP1-associated protein 1, functions as a JNK pathway
scaffold protein, binding both JNK and the upstream kinase MEKK1 in neurons [82]. SEP11,
septin-11, is a filament-forming cytoskeletal GTPase that plays a role in cytokinesis and vesicle
trafficking [83]. TPPP3, tubulin polymerization-promoting protein family member 3, has
microtubule binding activity and plays a role in cell proliferation and mitosis [84]. UCK2,
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uridine-cytidine kinase 2, catalyzes uridine and cytidine phosphorylation to uridine
monophosphate (UMP) and cytidine monophosphate (CMP), respectively [85]. GSS, Glutathione
synthetase, is involved in the glutathione biosynthesis pathway [86]. Glutathione synthesis has
been seen to be diminished in diabetic patients [87].
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CHAPTER 5: SUMMARY
In the present work, PP2Ac was found to interact either directly or indirectly with 202
interaction partners in primary human skeletal muscle cells and 19 PP2Ac interaction partners
were identified to show a significant change among the four treatment conditions (LGNI BAS,
LGNI INS, HGHI BAS and HGHI INS). Validating the important partners that may affect the
insulin signaling pathway (directly or indirectly) would be the next step. In addition, comparing
PP2Ac interaction partners in primary human skeletal muscle cells with/out HGHI treatment
with those from obese and type 2 diabetic participants will help to uncover the differences in the
PP2Ac interaction partners among the 3 groups. With this information, we may have a better
understanding of the role of PP2Ac in the insulin signaling pathway in primary human skeletal
muscle cells and ultimately better knowledge on the development of insulin resistance and type 2
diabetes.
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FIGURES

Figure 1. Insulin signaling pathway showing some of the signaling molecules involved and
the effects seen [10].
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Figure 2. Structure of the heterotrimeric PP2A holoenzyme [88].
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Figure 3. Clinical and proteomic data acquisition and analysis
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Figure 4. Proteomic data analysis
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Figure 5. Significantly enriched pathways for the 202 interaction partners and PP2Ac in
primary human skeletal muscle cells
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Figure 6. Interaction partners that showed significant difference among 4 treatment
groups. Mean of the normalized peak area for eachPP2Ac interaction partner in the LGNI
BAS samples was set to 1.00, and all the fold changes were relative to LGNI BAS. *:
p<0.05 vs. LGNI BAS, #: P<0.05 vs. HGHI BAS, and &: p<0,05 vs. LGLI INS
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TABLES
Table 1. Clinical characteristics for 8 lean participants in this study. Results were shown as
mean ± SEM. [Cutoff values]

Gender (M/F)

(4/4)
2

Body Mass Index (kg/m )

21.3 ± 2.2 [25]

HbA1C (%)

5.4 ± 0.2 [5.7]

Fasting Plasma Glucose (mg/dl)

84.9 ± 5.6 [100]

2h OGTT (mg/dl)

106.6 ± 15.1 [140]

M-value (mg/kg·min)

11.0 ± 3.1 [5]
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Table 2. The 202 protein groups that met the 2 criteria (See Methods for details) for
classification as PP2Ac interaction partners in primary human skeletal muscle cells. (*
indicates previously identified PP2A partners in INS-1 832/13 beta-cells).
Gene name

Protein name

PPP2R1A*

Serine/threonine-protein phosphatase 2A 65kDa regulatory subunit A
alpha isoform

PPP2R2A*

Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B
alpha isoform

PPP2R5D

Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit
delta isoform

PPP2R5E

Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit
epsilon isoform

A2M

Alpha-2-Macroglobulin

ACAT1

Acetyl-CoA Acetyltransferase 1, mitochondrial

ACP1*

Low molecular weight phosphotyrosine protein phosphatase; Acid
phosphatase 1, soluble

ACTA1

Actin, alpha skeletal muscle

ACTB, ACTG1

Actin, cytoplasmic 1; Actin, cytoplasmic 1, N-terminally processed;
Actin, cytoplasmic 2; Actin, cytoplasmic 2, N-terminally processed

ACYP2

Acylphosphatase-2;Acylphosphatase

ADA

Adenosine deaminase

AKR1B1

Aldose reductase
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AKR1C1,

Aldo-keto reductase family 1 member C1;Aldo-keto reductase family 1

AKR1C2,

member C2;Aldo-keto reductase family 1 member C3;Aldo-keto

AKR1C3, AKR1C4 reductase family 1 member C4
ALDH1A1

Retinal dehydrogenase 1

ALDH7A1

Alpha-aminoadipic semialdehyde dehydrogenase

ALDH9A1

4-trimethylaminobutyraldehyde dehydrogenase

AP2M1

AP-2 complex subunit mu

APOBEC2

Probable C->U-editing enzyme APOBEC-2

ASAH1

Acid ceramidase; Acid ceramidase subunit alpha; Acid ceramidase
subunit beta

ASMTL

N-acetylserotonin O-methyltransferase-like protein

ATP5D

ATP synthase subunit delta, mitochondrial

ATXN2L

Ataxin-2-like protein

BAP18, C17ORF49 Chromatin complexes subunit BAP18
BCAS3

Breast carcinoma-amplified sequence 3

BCAT1

Branched-chain-amino-acid aminotransferase, cytosolic

BOD1

Biorientation of chromosomes in cell division protein 1

BOLA2, BOLA2B

BolA-like protein 2

BROX, C1ORF58

BRO1 domain-containing protein BROX

C1QTNF5

Complement C1q tumor necrosis factor-related protein 5

C21ORF7, TAK1L

TAK1-like protein

CAPRIN1

Caprin-1

CAT

Catalase
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CCDC6*

Coiled-coil domain containing 6

CDV3

Protein CDV3 homolog

CHCHD3

Coiled-coil-helix-coiled-coil-helix domain-containing protein 3,
mitochondrial

CHMP1A

Charged multivesicular body protein 1a

CIAPIN1

Anamorsin

CIP29, SARNP

SAP domain-containing ribonucleoprotein

CKB

Creatine kinase B-type

CLCC1

Chloride channel CLIC-like protein 1

COMT

Catechol O-methyltransferase

COPS8

COP9 signalosome subunit 8

CORO1B

Coronin-1B

CPPED1

Calcineurin-like phosphoesterase domain-containing protein 1

CRYZ

Quinone oxidoreductase

CTPS

CTP synthase 1

CTSA

Lysosomal protective protein; Lysosomal protective protein 32 kDa
chain; Lysosomal protective protein 20 kDa chain

CTTN

Src substrate cortactin

CYCS

Cytochrome c

DBI

Acyl-CoA-binding protein

DCAMKL1

Doublecortin Like Kinase 1

DCTN3

Dynactin subunit 3

DDB1

DNA damage-binding protein 1
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DDX19B

ATP-dependent RNA helicase DDX19B

DLST*

Dihydrolipoamide S-succinyltransferase (E2 component of 2-oxoglutarate complex)

DR1

Protein Dr1

DYSF

Dysferlin

EIF2B1

Translation initiation factor eIF-2B subunit alpha

EIF4A3

Eukaryotic initiation factor 4A-III

EIF4H

Eukaryotic translation initiation factor 4H

ESD

S-formylglutathione hydrolase

ETF1

Eukaryotic peptide chain release factor subunit 1

EZR

Ezrin

FABP3

Fatty acid-binding protein, heart

FARSB

Phenylalanine--tRNA ligase beta subunit

FKBP1A

Peptidyl-prolyl cis-trans isomerase FKBP1A; Peptidyl-prolyl cis-trans
isomerase

FKBP9

Peptidyl-prolyl cis-trans isomerase FKBP9

FUBP1

Far upstream element-binding protein 1

GLRX3

Glutaredoxin-3

GMPPB*

GDP-mannose pyrophosphorylase B

GORASP2

Golgi reassembly-stacking protein 2

GPI

Glucose-6-phosphate isomerase

GPX1

Glutathione peroxidase 1

GRIPAP1

GRIP1-associated protein 1
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GSPT1

Eukaryotic peptide chain release factor GTP-binding subunit ERF3A

GSS

Glutathione synthetase

H2AFJ, H2AFV,

Histone H2A.x; Histone H2A type 1-A; Histone H2A type 1-B/E;

H2AFX, H2AFZ,

Histone H2A type 1; Histone H2A type 1-D; Histone H2A type 2-A;

HIST1H2AA,

Histone H2A type 3; Histone H2A type 1-C; Histone H2A type 2-B;

HIST1H2AB,

Histone H2A type 2-C; Histone H2A.J; Histone H2A type 1-H; Histone

HIST1H2AC,

H2A type 1-J; Histone H2A.Z; Histone H2A.V; Histone H2A

HIST1H2AD,
HIST1H2AG,
HIST1H2AH,
HIST1H2AJ,
HIST2H2AA3,
HIST2H2AB,
HIST2H2AC,
HIST3H2A
HINT1

Histidine triad nucleotide-binding protein 1

HIST1H1E

Histone H1.4

HIST1H4A

Histone H4

HMGCS1

Hydroxymethylglutaryl-CoA synthase, cytoplasmic

HN1

Hematological and neurological expressed 1 protein

HSPA4L

Heat shock 70 kDa protein 4L

HSPB6

Heat shock protein beta-6

HSPE1

10 kDa heat shock protein, mitochondrial
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HTRA1

Serine protease HTRA1

IDH1

Isocitrate dehydrogenase [NADP] cytoplasmic

IGBP1*

Immunoglobulin (CD79A) binding protein 1

IMPA1

Inositol monophosphatase 1

IST1

IST1 homolog

ITGA5

Integrin alpha-5; Integrin alpha-5 heavy chain; Integrin alpha-5 light
chain

IVD

Isovaleryl-CoA dehydrogenase, mitochondrial

KHSRP

Far upstream element-binding protein 2

LSS

Lanosterol synthase

LYPLA1

Acyl-protein thioesterase 1

MAN2B1

Lysosomal alpha-mannosidase; Lysosomal alpha-mannosidase A
peptide; Lysosomal alpha-mannosidase B peptide; Lysosomal alphamannosidase C peptide; Lysosomal alpha-mannosidase D peptide;
Lysosomal alpha-mannosidase E peptide

MATR3

Matrin-3

METTL11A

Alpha N-terminal protein methyltransferase 1A

MPI

Mannose-6-phosphate isomerase

MVD

Diphosphomevalonate decarboxylase

MYOM3

Myomesin-3

NAMPT*

Nicotinamide phosphoribosyltransferase

NASP

Nuclear autoantigenic sperm protein

NIT2

Omega-amidase NIT2
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NME1, NME2,

Nucleoside diphosphate kinase; Nucleoside diphosphate kinase B;

NME2P1

Putative nucleoside diphosphate kinase

NSFL1C

NSFL1 cofactor p47

NUDCD2

NudC domain-containing protein 2

NUDT5

ADP-sugar pyrophosphatase

OSBPL9

Oxysterol-binding protein; Oxysterol-binding protein-related protein 9

OXCT1

Succinyl-CoA:3-ketoacid-coenzyme A transferase 1, mitochondrial

PCBP2*, PCBP3*

Poly(rC)-binding protein 2; Poly(rC)-binding protein 3

PCMT1

Protein-L-isoaspartate O-methyltransferase; Protein-L-isoaspartate(Daspartate) O-methyltransferase

PDCD5

Programmed cell death protein 5

PDHX*

Pyruvate dehydrogenase protein X component, mitochondrial

PDLIM4

PDZ and LIM domain protein 4

PEBP1

Phosphatidylethanolamine-binding protein 1; Hippocampal cholinergic
neurostimulating peptide

PEPD

Xaa-Pro dipeptidase

PFDN1

Prefoldin subunit 1

PFDN2

Prefoldin subunit 2

PFN1

Profilin-1

PGM3

Phosphoacetylglucosamine mutase

PHB

Prohibitin

PMPCA

Mitochondrial-processing peptidase subunit alpha

POLR2H

DNA-directed RNA polymerases I, II, and III subunit RPABC3
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PPP4C*

Serine/threonine-protein phosphatase 4 catalytic subunit;
Serine/threonine-protein phosphatase

PPP4R1

Serine/threonine-protein phosphatase 4 regulatory subunit 1

PPP4R2*

Serine/threonine-protein phosphatase 4 regulatory subunit 2

PRDX2

Peroxiredoxin-2

PRKACA,

cAMP-dependent protein kinase catalytic subunit beta; cAMP-

PRKACB

dependent protein kinase catalytic subunit alpha

PROSC

Proline synthase co-transcribed bacterial homolog protein

PSMA6*

Proteasome subunit alpha type; Proteasome subunit alpha type-6

PSMB4

Proteasome subunit beta type-4

PTER

Phosphotriesterase-related protein

PTK2

Focal adhesion kinase 1

PTMS

Parathymosin

QKI

Protein quaking

QTRT1

Queuine tRNA-ribosyltransferase

RAB11A, RAB11B Ras-related protein Rab-11B;Ras-related protein Rab-11A
RABEP2

Rab GTPase-binding effector protein 2

RAD23A

UV excision repair protein RAD23 homolog A

RAPH1

Ras-associated and pleckstrin homology domains-containing protein 1

RPS21

40S ribosomal protein S21

RPSA, RPSAP58

40S ribosomal protein SA

RSU1

Ras suppressor protein 1

RTCD1

RNA 3-terminal phosphate cyclase
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RTN1

Reticulon-1

S100A13

Protein S100-A13

S100A4

Protein S100-A4

S100Z

Protein S100-Z

SAR1A

GTP-binding protein SAR1a

SARS

Serine--tRNA ligase, cytoplasmic

SBDS

Ribosome maturation protein SBDS

SCRN1

Secernin-1

SEP11

Septin-11

SERPINB1

Leukocyte elastase inhibitor

SERPINB6

Serpin B6

SERPINC1

Antithrombin-III

SERPINE1

Plasminogen activator inhibitor 1

SET

Protein SET

SETD7

Histone-lysine N-methyltransferase SETD7

SF3A1

Splicing factor 3A subunit 1

SFPQ

Splicing factor, proline- and glutamine-rich

SLC9A3R1

Na(+)/H(+) exchange regulatory cofactor NHE-RF1

SNX1

Sorting nexin-1

SNX12

Sorting nexin-12

SNX17

Sorting nexin-17

SOD1

Superoxide dismutase [Cu-Zn]

SORD

Sorbitol dehydrogenase

45
SPAG7

Sperm-associated antigen 7

SRP9

Signal recognition particle 9 kDa protein

SSBP1*

Single-stranded DNA-binding protein, mitochondrial

ST13, ST13P5

Hsc70-interacting protein; Putative protein FAM10A5

STMN1

Stathmin

SWAP70

Switch-associated protein 70

SYNPO2L

Synaptopodin 2-like protein

TBCA

Tubulin-specific chaperone A

TCEB2

Transcription elongation factor B polypeptide 2

TFG

Protein TFG

THBS1

Thrombospondin-1

TMEM189,

Ubiquitin-conjugating enzyme E2 variant 1

UBE2V1
TMF1

TATA element modulatory factor

TMSB10

Thymosin beta-10

TMSB4X

Thymosin beta-4; Hematopoietic system regulatory peptide

TPM2

Tropomyosin beta chain

TPP1

Tripeptidyl-peptidase 1

TPPPP3

Tubulin polymerization-promoting protein family member 3

TSG101

Tumor susceptibility gene 101 protein

TTC17

Tetratricopeptide repeat protein 17

TTC9

Tetratricopeptide repeat protein 9A
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TUBA1A,

Tubulin alpha-1B chain; Tubulin alpha-1A chain

TUBA1B
TUBB6*

Tubulin beta-6 chain

TXNDC5

Thioredoxin domain-containing protein 5

TXNL1

Thioredoxin-like protein 1

TXNRD1

Thioredoxin reductase 1, cytoplasmic

UAP1

UDP-N-acetylhexosamine pyrophosphorylase; UDP-Nacetylgalactosamine pyrophosphorylase; UDP-N-acetylglucosamine
pyrophosphorylase

UBE2D3

Ubiquitin-conjugating enzyme E2 D3

UBL4A

Ubiquitin-like protein 4A

UCK2

Uridine-cytidine kinase 2

VPS25*

Vacuolar protein-sorting-associated protein 25

VTA1*

Vacuolar protein sorting-associated protein VTA1 homolog

VWA5A

von Willebrand factor A domain-containing protein 5A

ZNF157

Zinc finger protein 157
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Table 3. Significantly enriched pathways for the PP2Ac interaction partners identified in

Number of
PP2Ac
interaction
partners in
the study

Gene Names

-log(p-value)

DAVID
Pathways

this study revealed by DAVID pathway analysis

BCAT1, DLST, PEPD, CTPS,
SARS, LYPLA1, CKB, GSS,

Carboxylic acid
2.83
metabolic process

AKR1C3, AKR1C2, GPI, FARSB,

18

FABP3, QKI, IDH1, PDHX,
AKR1C1, ALDH9A1
RPSA, EIF4A3, GSPT1, EIF4H,

Protein
2.82
biosynthesis

SARS, RPSAP58, FARSB, ETF1,

9

RPS21, EIF2B1
ST13, PFDN2, FKBP9, PFDN1,
Protein folding

2.63

TBCA, HSPA4L, TTC9, HSPE1,

9

FKBP1A
ACTB, FKBP9, RPSA, ETF1,
Protein
2.37
metabolism

EIF2B1, PFDN2, PFDN1, TBCA,
RPSAP58, EIF4H, TUBB6,
TUBA1A, RPS21, TUBA1B

13
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PPP2R1A, PPP4R1, PPP2CA,

FGF signaling
2.31
pathway

PPP2R5D, PPP2CB, PEBP1,

8

PPP2R5E, PPP2R2A
Pyruvate

ALDH7A1, AKR1B1, ACYP2,
1.97

Monosaccharide
biosynthetic

5
ACAT1, ALDH9A1

metabolism

PGM3, GPI, UAP1, SORD
1.90

4

process

Signaling by Wnt

1.87

PSMB4, PPP2R1A, PSMA6,

6

PPP2CA, PPP2R5D, PPP2CB
Amino sugar and
nucleotide sugar

GMPPB, PGM3, GPI, UAP1, MPI
1.83

5

metabolism
Alcohol
biosynthetic

PGM3, GPI, UAP1, SORD
1.69

4

process
ACTG1, PFN1, TPPP3, PTK2, EZR,

Cytoskeleton
1.53
organization

ACTA1, TMSB4X, TMSB10,
STMN1, SOD1, PPP4C, TUBA1B

12
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Regulation of

PPP2R1A, GPX1, PPP2CA,

intracellular

UBE2V1, TFG, PEBP1, FKBP1A,
1.33

protein kinase

8
CAT, TMEM189

cascade

Table 4. Interaction partners that showed significant difference upon insulin stimulation.

Fold
Fold
change
Protein Name

Gene Name

Fold
Fold change

change
LGNI

change
HGHI BAS

LGNI INS

HGHI INS

BAS
Low molecular
weight
ACP1

1.00±0.85

0.44±0.12

1.79±1.59

0.25±0.08#

1.00±0.43

2.05±0.54

9.04±8.28*

1.65±0.05

1.00±0.72

0.73±0.28

2.74±2.41

0.22±0.1&

1.00±0.42

4.03±1.46*

23.95±19.63

1.74±0.49

1.00±0.99

0.05±0.03

0.03±0.02

0.07±0.05#

phosphotyrosine
protein phosphatase
N-acetylserotonin
OASMTL
methyltransferaselike protein
TAK1L

TAK1-like protein
Coiled-coil domain-

CCDC6
containing protein 6
CYCS

Cytochrome c
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Serine/threonineDCAMKL1

1.00±0.54

2.09±1.01

1.40±0.97

0.64±0.23&

1.00±0.75

1.33±0.53

2.43±1.69*

0.23±0.06&

1.00±0.21

2.87±0.96*

16.89±15.68*

1.29±0.36

1.00±0.99

0.02±0.01

0.10±0.10*

0.01±0

1.00±0.76

0.42±0.1

2.23±1.87

0.24±0.07&

1.00±0.94

0.67±0.48

1.17±0.92

0.49±0.45&

1.00±0.72

2.83±1.08

3.31±2.45*

0.68±0.40#,&

1.00±0.33

3.5±1.76

7.37±3.15

4.02±2.29#

1.00±0.32

1.67±0.63

3.58±2.48

0.76±0.23&

Protein quaking

1.00±0.88

0.45±0.17

3.8±3.35*

0.68±0.32

Protein S100-A13

1.00±0.51

0.43±0.07

0.98±0.76

0.21±0.05&

Septin-11

1.00±0.54

0.82±0.34

1.93±1.18

0.42±0.19&

protein kinase
DCLK1
S-formylglutathione

ESD
hydrolase
GLRX3

Glutaredoxin-3
Glutathione

GPX1
peroxidase 1
GRIP1-associated
GRIPAP1
protein 1
Glutathione
GSS
synthetase
Histidine triad
HINT1

nucleotide-binding
protein 1
Heat shock protein

HSPB6
beta-6
ImmunoglobulinIGBP1
binding protein 1
QKI
S100A13
SEP11
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Tubulin
polymerizationTPPP3

1.00±0.88

0.59±0.27

1.09±0.91

0.14±0.07&

1.00±0.59

0.4±0.11

1.5±1.34

0.19±0.03&

promoting protein
family member 3
Uridine-cytidine
UCK2
kinase 2

Data are given as fold changes (means ± SEM). Peak area for each protein identified in a
specific sample was normalized against the peak area for PP2Ac identified in the same sample
(See Methods). The normalized peak area for each PP2Ac interaction partner was compared
among the 4 sets of samples to assess effects of acute insulin stimulation or effects of
hyperinsulinemia hyperglycemia on protein-protein interactions involving PP2Ac. Mean of the
normalized peak area for eachPP2Ac interaction partner in the LGNI BAS samples was set to
1.00, and all the fold changes were relative to LGNI BAS. *: p<0.05 vs. LGNI BAS, #: P<0.05
vs. HGHI BAS, and &: p<0,05 vs. LGLI INS.
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PROTEIN PHOSPHATASE 2A: FUNCTION AND REGULATION IN
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Protein Phosphatase 2A (PP2A), a major serine/threonine phosphatase involved in
insulin signaling pathway, plays a critical role in the development of insulin resistance
and type 2 diabetes (T2D), which is characterized with hyperinsulinemic hyperglycemic
condition. Moreover, majority of the glucose disposal takes place in the skeletal muscle
which is also the main tissue responsible for insulin resistance. The catalytic subunit of
PP2A (PP2Ac) can interact with multiple regulatory subunits and other regulatory
proteins as well as substrates. These interactions are important for maintain normal PP2A
function and subsequent cell signaling. We hypothesized that hyperinsulinemic
hyperglycemic condition and insulin stimulation would result in differentially changed
protein-protein interactions involving PP2Ac in primary human skeletal muscle cells
derived from lean healthy participants.
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Using UPLC-nanoESI-MS/MS, 202 PP2Ac interaction partners were identified in
primary human skeletal muscle cells from 8 lean heathy participants. Out of which 18
partners were previously identified in the islet beta cells by our group. In addition, 19
interaction partners of PP2Ac showed a significant difference among 4 treatment groups:
low glucose no insulin without acute 15-min insulin treatment (LGNI BAS), low glucose
no insulin with acute 15-min insulin treatment (LGNI INS), high glucose high insulin
without acute 15-min insulin stimulation (HGHI BAS) and high glucose high insulin with
acute 15-min insulin stimulation (HGHI INS). Under basal conditions (i.e., without
acute 15-minute insulin stimulation), 6 proteins showed a significant change in PP2Ac
interaction between the low glucose no insulin and chronicle hyperinsulinemia and
hyperglycemia conditions (LGNI BAS vs HGHI BAS, p<0.05). In addition, 2 proteins
showed significant difference in PP2Ac interaction in LGNI condition in response to
insulin stimulation (LGNI BAS vs LGNI INS, p<0.05). In HGHI conditions, 4 proteins
showed significant difference in PP2Ac interaction in response to insulin stimulation
(HGHI Bas vs HGHI INS, p<0.05). Upon acute insulin stimulation, 11 proteins showed
significant difference in PP2Ac interaction in HGHI condition when compared to the
LGNI condition (LGNI INS vs HGHI INS, p<0.05). These differential changes of PP2Ac
interaction partners among the 4 treatments provide new information regarding PP2A in
primary human skeletal muscle cells under hyperinsulinemic hyperglycemic conditions.
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